Global experts in diagnostic medicine, medical physics and image analysis
LiverMultiScan is suitable for monitoring effects during interventional trials.
We have developed a dedicated research service, LiverMultiScan Discover, in response to the enhanced requirements of our research partners, including volumetric burden of disease.
LiverMultiScan Discover currently supports a number of clinical and preclinical trials for drugs under assessment for treatment of non-alcoholic fatty liver disease – NAFLD – and non-alcoholic steatohepatitis (NASH), including Galectin’s Phase 2 GR-MD-02 trial.
Contact us today to see how LiverMultiScan can make the difference in your clinical trial.
22 yr old Oxford man with PSC and AIH overlap syndrome; response to prednisolone and azathioprine over 20 months.
LIF score decreased from 3.4 to 1.4.
LiverMultiScan is unique in that it was designed by a team of physicians and scientists in collaboration, and so has been optimized for general clinical use from the outset. It is generalizable, and completely safe.
Contact us today to learn more about early efficacy signals, surrogate endpoints and screening and enrichment for optimization of patient cohorts in clinical trials.
This is the first demonstration of a non-invasive test to differentiate early stages of fibrosis from normal liver.
Obese subject before & after bariatric surgery. Initially (Top Image), cT1 is 973ms, lipid content 21%. After 11 months of weight loss (Bottom Image) cT1 of 817ms, lipid content of 1.4%. This shows the power of LiverMultiScan to monitor therapy.